Introduction
The cost of sequencing your genome has dramatically fallen. Wearables are affordable. A new generation of peptides is flooding the market. But what does any of it actually mean for your health — and how do you separate what's genuinely useful from the noise?
In this candid conversation, two physicians working at the forefront of longevity and synthetic biology will cut through the hype. They'll share the frameworks they use to ask better questions, interpret genomic data, and evaluate emerging peptide therapies — and offer their unfiltered view of where personalised medicine is actually headed.
An evening for the curious and the rigorous.
Speakers
Zara Butte, M.D. is a board-certified internal medicine physician and clinical strategist. She focuses on early disease detection and prevention, particularly in cardiometabolic health. Her clinical approach incorporates precision medicine techniques and integrative approaches to health and longevity, especially for women.
Dr David Kim BM BCh (MD) is a Biologist, XPRIZE winner and a former officer in the British Army. As a physician, he has worked in remote locations in the DR Congo and Sierra Leone and is passionate about using synthetic biology to lower the cost of advanced medicines.
Collin Jarvis is Senior Director of Business Development at Human Longevity, Inc., where he helps individuals and organizations access advanced preventive health programs. A former UC Berkeley track and field captain and lifelong endurance athlete, Collin brings a personal interest in performance, resilience, and proactive health to his role as moderator.
Hosted by
HLI — Most people only see a doctor when something feels wrong. By then, the window for meaningful intervention has often closed. Human Longevity was built on a different premise: that biology gives us signals long before disease becomes visible — and that catching those signals early is the difference between prevention and treatment.
General Bio is a frontier pharmaceutical company, making low-cost oral GLP-1 and peptides inside edible microbes that act as protective capsules for drug delivery. The mission is to bring to market the world's first oral GLP-1 in the form of a shelf-stable 20g powder eaten daily, that becomes both distributable and affordable for the 1 billion people living with obesity globally.
Event format
Walk-in clinic 1400-1700
945 Market Street
945 Market St, San Francisco, CA 94103, USA
VIP Lounge